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Context:Thyrotropin (TSH)-secretingpituitary adenomas (TSHomas) area rare causeofhyperthyroidism,
and the genetic aberrations responsible remain unknown.
Objective: To identify somatic genetic abnormalities in TSHomas.
Design and Setting: A single-nucleotide polymorphism (SNP) array analysis was performed on 8
TSHomas. Four tumors with no allelic losses or limited loss of heterozygosity were selected, and
whole-exome sequencing was performed, including their corresponding blood samples. Somatic
variants were confirmed by Sanger sequencing. A set of 8 tumors was also assessed to validate
candidate genes.
Patients: Twelve patients with sporadic TSHomas were examined.
Results: The overall performance of whole-exome sequencing was good, with an average coverage
of each base in the targeted region of 97.6%. Six DNA variants were confirmed as candidate driver
mutations, with an average of 1.5 somatic mutations per tumor. Nomutations were recurrent. Two
of thesemutations were found in geneswith an established role inmalignant tumorigenesis (SMOX
and SYTL3), and 4 had unknown roles (ZSCAN23, ASTN2, R3HDM2, and CWH43). Similarly, an SNP
array analysis revealed frequent chromosomal regions of copy number gains, including recurrent
gains at loci harboring 4 of these 6 genes.
Conclusions: Several candidate somatic mutations and changes in copy numbers for TSHomas were
identified. The results showed no recurrence of mutations in the tumors studied but a low number
of mutations, thereby highlighting their benign nature. Further studies on a larger cohort of
TSHomas, along with the use of epigenetic and transcriptomic approaches, may reveal the un-
derlying genetic lesions. (J Clin Endocrinol Metab 102: 566–575, 2017)
Thyrotropin (TSH)-secreting pituitary adenomas(TSHomas) account for 0.5% to 2.8% of all pituitary
adenomas, and an increasing number of these tumors
have been reported during the last decade (1, 2). Al-
though goiter and hyperthyroidism are hallmark features
in patients with these tumors, many plurihormonal tu-
mors also present with the features of excess growth
hormone and prolactin (3, 4). Similarly, because most of
these tumors are macroadenomas and are invasive,
neurologic features, such as ocular symptoms and
headaches due to mass effects, also cause considerable
morbidity (4). Surgery remains the treatment of choice;
however, surgical resection is often incomplete for
macroadenomas, and, consequently, most research re-
cently performed has focused on medical management
(5–7). Therefore, elucidating the genetic events that
underlie TSHomas could lead to advances in their
management.
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The molecular mechanisms underlying tumorigenesis
in TSHomas have not yet been clarified. Although these
tumors are considered to be monoclonal in origin (8), no
intrinsic genetic defects in common proto-oncogenes or
tumor suppressor genes (TSGs) leading to tumor initia-
tion or promotion have been identified. Germ-line mu-
tations in the AIP and MEN1 genes have been reported
(9, 10); however, such familial occurrence constitutes
only a small number of cases, with most of these tumors
being sporadic. Similarly, although candidate gene
screening approach using polymorphic markers have
detected loss of heterozygosity (LOH) at theMEN1 gene
locus (11q13) in a small number of TSHomas, a con-
current mutation in theMEN1 gene was not found in the
same samples (11). Furthermore, mutant isoforms of
thyroid hormone receptors were searched as possible
candidate oncogenes to explain the refractoriness of these
tumors to the inhibitory effects of triiodothyronine;
however, mechanisms other than mutations were more
likely to account for the phenomenon of inappropriate
TSH secretion in these tumors (12, 13). Moreover, in
contrast to somatotropinomas, in which somatic muta-
tions in the a-subunit of the stimulatory G (GNAS) gene
have been detected in up to 40% of tumors (14–16),
screening for the G protein subunits Gaq, Ga11, and
Gas, as well as the thyrotropin (TSH)-releasing hormone
receptor among TSHomas, did not reveal the activating
mutation (17). More recently, mutations in an orphan G
protein–coupled receptor, GPR101, and the deubiquiti-
nase gene, USP8, have been reported in somato-
tropinomas and Cushing disease, respectively (18, 19).
However, USP8 and GPR101 mutations in TSHomas
have not yet been reported. Besides mutations, several
chromosomal aberrations have been described in various
pituitary tumors using comparative genomic hybridiza-
tion as well as whole-genome sequencing and single-
nucleotide polymorphism (SNP) array technology (15,
20). However, genetic studies involving TSHomas are
limited or have been conducted by using only a small
number of isolated markers.
The use of an array-based SNP analysis is an efficient
method for a genome-wide copy number analysis as well
as for the detection of cryptic chromosomal changes, such
as LOH; it has also been successfully used for a wide
range of tumors (21–23). Similarly, whole-exome se-
quencing (WES) is a well-validated approach to identify
mutations and has been used in several tumor types,
including pituitary adenomas (24). In the current study,
we conducted a combinatorial approach using an SNP
array analysis and WES to identify the genetic landscape
of TSHomas. Using WES, we identified 6 candidate
mutations. Although these mutations were not recurrent,
considering the rarity of TSHomas, we attempted to
highlight the somatic landscape of these very rare tumors,
and our results provide important information for future
studies directed toward detecting tumorigenesis in these
tumors. Furthermore, focal as well as chromosomal arm-
length copy number gains were frequent and were a more
recurrent finding than losses. In addition, we found
several broad regions of copy number–neutral loss of
heterozygosity (cnLOH).
Materials and Methods
Patient material
Twelve patients with TSHomas were included in the current
study (Table 1). Written informed consent was obtained from
all participants, and the Ethics Committee of Gunma University
and Toranomon Hospital approved the study. Hormonal
studies on all patients showed elevated free triiodothyronine
and free thyroxine levels; 7 patients had elevated TSH levels.
Seven of the resected tumors were microadenomas, and 5 were
macroadenomas. All tumors were histologically confirmed as
TSHomas and preserved in RNAlater (ThermoFisher Scientific,
Waltham, MA) immediately after surgery. The first set of 8
tumor sampleswas randomly selected for the SNP array. Four of
these samples, which had no or a limited region of LOH,
constituted the discovery set for WES. The remaining 4 tumor
samples and 4 additional samples (8 tumor samples total)
constituted the validation set.
Isolation of genomic DNA
DNA was isolated from tumor and blood samples by using
the commercially available Qiagen tissue kit (Qiagen, Hilden,
Germany) and a Genomix kit (Austin, TX), respectively,
according to the manufacturer’s guidelines. All specimens were
quantified by using PicoGreen® (ThermoFisher Scientific).
SNP array analysis
The HumancytoSNP-12v2.1 BeadChip kit (Illumina Inc.,
San Diego, CA) was used to perform a genome-wide SNP array.
Genomic DNA from tumors was hybridized to the BeadChip by
using the Illumina protocol, and arrays were imaged by using
the IlluminaHiScan system.Manufacturer-provided cluster files
were used to make genotype calls, and data were analyzed by
examining the allelic composition and signal intensity.
Whole-exome capture, sequencing, and
bioinformatics analysis
Exome enrichment was performed by using the SureSelect
Human All Exon V5 target enrichment technique (Agilent
Technologies, Santa Clara, CA), and libraries were prepared
according to the standard Illumina protocol for paired-end
sequencing. Sequencing was performed on the Illumina
HiSeq2000 platform outputting 100–base pair reads. Se-
quencing data were aligned to hg19/GRCh37 using the
Burrows-Wheeler aligner (version 0.7.8). Single-nucleotide
variants (SNVs) and small insertions and deletions (indels)
were identified by using SomaticSniper, version 1.0.3 (The
Genome Institute atWashington University School ofMedicine,
St. Louis, MO), and GATK SomaticIndel Detector, version 1.6
(Broad Institute, Cambridge, MA), respectively.
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Sequence validation
Tumor-specific variants were confirmed by Sanger se-
quencing using the BigDye Terminator, version 3.1, cycle se-
quencing kit (ThermoFisher Scientific) andABI 3730 automated
capillary sequencer (ThermoFisher Scientific). The confirmed
DNA variants were further assessed in a validation set of 8
tumors.
The method used in this study is described in detail in the
Supplemental Materials and Methods.
Results
Analysis of chromosomal copy number alterations
The overall pattern of copy number alterations found
by using the SNP array analysis among TSHomas is
shown in Fig. 1. Copy number changes involving the
whole chromosome (the entire p and q arm) signifying an
aneuploidy event were common, with 62.5% of tumors
showing at least 1 whole chromosome copy number gain
or loss (Supplemental Table 1). Similarly, a long single
stretch of copy number alterations involving the gain of
an entire arm of the chromosome (the entire p or q arm),
referred to here as a chromosomal arm-length gain, was
most frequent on 4p, 5p, 7p, and 19q (50%, 4 of 8
samples), followed by 4q, 15q, 16p, 19p, and 21q
(37.5%, 3 of 8 samples) (Supplemental Table 2). Copy
number gain at 15q is of particular interest because it
harbors the locus for the USP8 gene (19). In contrast to
gains, chromosomal arm-length losses were infrequent
and noted only on the chromosomal arms 18p and 18q
(tumor sample 1).
Regional analysis of copy number changes
In a regional analysis of copy number alterations, 106
regions (range, 0 to 41 per sample) of focal (less than the
chromosomal arm-length) gains were found. All focal
gains are presented in Supplemental Table 3. Tumor
sample 5 showed the highest number of focal gains be-
cause of the high number of these events, particularly on
chromosome 1p and chromosome 2. Chromosome 1p on
this sample harbored 9 regions, and chromosome 2 had
22 regions of focal gains mainly clustered in its p arm; all
these closely spaced focal gains were the gain of a single
copy number (Supplemental Tables 3 and 4). This pat-
tern resembles the SNP array-based finding of the
chromothripsis-like pattern (23, 25). In addition, multi-
ple loci of recurrent gains were detected. Although most
of these gains were a single copy gain, the recurrent gain
of 2 copies was observed across 7 loci (1q31.1-32.1, 1q41,
1q43, 7p21.3-21.2, 7p12.1-11.2, 7q21.11-21.13, and
13q31.1-31.3) (Supplemental Table 4). Several of these
loci harbor genes formicro-RNA; importantly, recurrently
targeted loci 1q31.1-32.1, involved in copy number gains
in 50% of our tumors, harbored the BRINP3 gene, which
was previously reported in relation to gonadotrope-cell
pituitary adenoma (26). Similarly, the focal gain at
chromosome 20q (position: 31733956-58602753) on
Table 1. Clinical Details of All Patients With TSHomas
Tumor
Sample
No.
Age
(y) Sex
Tumor
Size
Histology
(Immunostaining) MIB-1 (%)
Basal Hormone Levels
Preoperative
Treatment
TSHa
(pg/mL)
FT3b
(pg/mL)
FT4c
(ng/dL)
GHd
(ng/mL)
PRLe
(ng/mL)
1 30 M Micro TSH, PRL 2 3.584 10.46 2.24 ,0.1 2.8 —
2 37 M Micro TSH, GH ,1.0 4.564 5.76 2.01 ,0.1 10.8 SSA
3 37 F Micro TSH, GH, PRL 0.3 1.892 4.83 1.75 3.9 17.9 —
4 20 M Macro TSH, PRL 1 10.565 7.88 1.84 1 51.4 SSA
5 46 F Micro TSH 1.5 4.976 5.1 1.77 ,0.1 19.6 —
6 33 F Micro TSH ,1.0 2.28 7.3 3.4 0.6 14.9 SSA
7 32 F Micro TSH, GH 0.2 5.22 4.93 2.5 0.3 9.5 SSA
8 45 F Macro TSH 1.2 2.349 5.72 1.8 0.6 0.2 DA
9 25 F Macro TSH, PRL * 8.14 5.81 2.23 1.7 15.5 SSA
10 19 F Macro TSH, PRL * 1.52 4.22 1.94 0.6 17.1 SSA
11 28 F Macro TSH * 5.45 28.33 7.77 0.87 1.9 SSA
12 50 F Micro TSH * 8.88 5.56 2.49 0.56 17 SSA
—Patients 1, 3, and 5 did not receive SSA or DA before surgery. *MIB-1% data not available for tumor samples 9–12.
Abbreviations: DA, dopamine agonist; F, female; GH, growth hormone; M, male; MIB-1%, cell proliferation marker-labeling index; PRL, prolactin; SSA,
somatostatin analog.
aReference range: 0.54–4.26 mIU/mL.
bReference range: 2.29–4.17 pg/mL.
cReference range: 0.72–1.52 ng/dL.
dReference range: ,2.1 ng/mL.
eReference range: 4.4–31.2 ng/mL.
568 Sapkota et al Whole-Exome Sequencing of TSHomas J Clin Endocrinol Metab, February 2017, 102(2):566–575
Downloaded from https://academic.oup.com/jcem/article-abstract/102/2/566/2972048
by Gunma University user
on 15 February 2018
tumor sample 7 harbored theGNAS gene, which together
with the 20q chromosomal arm-length gain on tumor
samples 1 and 8 represent important loci involved in the
copy number gain in 37.5% of tumor samples.
In contrast to focal gains, only 2 tumors showed focal
losses. Hemizygous deletion leading to focal loss was iden-
tified in tumor sample 4 (chromosome 15) and tumor sample
8 (chromosome22) (Figs. 1 and2andSupplementalTable 5).
Copy number-neutral LOH
Several broad regions of LOH without any change in
the copy number were found in our SNP array analysis.
These areas of copy number-neutral LOH (cnLOH) were
common, with 62.5% of TSHomas harboring at least 1
cnLOH event. Our results showed that 66 regions across
11 chromosomes ranging in size from 1.29Mb to 67Mb
were involved in cnLOH (Figs. 1 and 2; Supplemental
Table 6). As shown in Figs. 1 and 2, tumor samples 3, 6,
and 7 harbored no cnLOH events, whereas tumor sample
1 had cnLOH involving 4 chromosomes and tumor
samples 2, 4, and 8 had cnLOH involving 2 chromo-
somes. Chromosomes 5, 7, and X (tumor sample 5) and
chromosome 12 (tumor sample 2) had limited cnLOH
regions, and chromosomes 1, 6, 8, 10, 11, 18, and 22 had
larger regions involved in cnLOH. The most common
region involved in cnLOH was in chromosomes 1p and 8
(25% each, 2 of 8 samples). Recurrent cnLOH at 1p on
tumor sample 1 (position: 48723161-54018483, 5.29 Mb)
and tumor sample 4 (position: 38201371-54633847, 16Mb)
contained loci for the CDKN2C gene, which codes for
proteins involved in cell-cycle regulation. Similarly, cnLOH
at chromosome 11 (position: 55091268-73356872, 18Mb)
on tumor sample 1 harbored loci for MEN1 and AIP.
The largest cnLOH event (position: 44936177-112494578,
67 Mb) on chromosome 10 in tumor sample 1 harbored
10q21.1 loci, 1 of the 3 significant susceptibility loci for
sporadic pituitary adenoma reported by Zhou et al. in a
genome-wide association study (27).All cnLOHeventswere
located in regions of segmental duplication, and almost half
of them were on previously identified fragile sites (28).
Because mutant allele frequencies in tumor DNA are
consistent with mutations being heterozygous in nature,
we included TSHoma samples with no LOH (tumor
samples 3, 6, and 7; Fig. 2) or minimal LOH (tumor
sample 5; Fig. 2) for theWES study. A similar approach to
WES has been successfully used to study aldosterone-
producing adenomas (29).
Identification of tumor-specific somatic variants in a
discovery cohort
WESwas performed on 4 tumors (tumor samples 3, 5,
6, and 7; Table 1) and their matched leukocyte samples.
Figure 1. Overview of the pattern of copy number alterations in TSH-secreting adenomas across autosomal chromosomes. The genomic location
and size of the copy number variant and LOH events are depicted on the left side of the ideograms for tumor samples 1 to 8 (position based on
GRCh37). Green bars, orange bars, and gray bars represent copy number gains, copy number losses, and copy neutral LOH events, respectively.
The red mark within the ideogram represents the centromere. Copy number gains and copy number-neutral LOH were more common than copy
number losses. (Note: closely spaced focal gains at chromosome 2 on tumor 5, as well as closely spaced cnLOH in tumor samples, appear in
a single small bar.) The graph was plotted by using KaryoStudio software (Illumina Inc.). Chromosomal gains found in sex chromosomes are
shown in Supplemental Fig. 1.
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On average, 4.7 Gb of high-quality sequence data were
generated per sample. Of sequence reads, 99.98% were
aligned to the human reference genome (hg19/GRCh37).
The average distinct coverage of each base in the targeted
region was 97.63%, with 66.71% of the targets covered
to a depth of 50X. The summary statistics of WES are
presented in Supplemental Table 7.
Consistent with the absence of a family history, none
of the matched leukocyte samples showed germline
mutations in the following genes: MEN1, CDKN1B,
AIP, and PRKAR1A, which are known to be associated
with familial pituitary adenomas. As shown in Table 2,
WES identified a total of 1003 (250.75/tumor) high-
quality SNVs and tumor-specific indels, among which
108 variants were predicted to be functionally damaging
variants, including 67 missense, 20 simple insertion and
deletion, 11 frame-shift, 7 splice-site, and 3 nonsense
variants. Seventeen of these variants were previously
unreported somatic DNA variants. Because 3 of these
unknown variants (HLA-DRB1, HLA-DQA1 [in tumor
sample 3], and CYP21A2 [in tumor sample 5]) occurred
in the highly polymorphic human leukocyte antigen re-
gion, we selected the remaining 14 genes as bearing
probable candidate driver mutations. Sanger sequencing
performed on these 14 variants confirmed 6 of them (Fig. 3;
Supplemental Table 9), with an average of 1.5 confirmed
putative somatic mutations per tumor (range, 0 to 4 per
sample). All 6 somatic DNA variants were heterozygous
SNVs. Five of the 6 variants (83.3%) were missense
changes, whereas 1 was a nonsense variant (16.6%). Two
of these variants, involving the genes ZSCAN23 and
SYTL3, occurred across chromosome 6, and 1 variant each
Figure 2. (A) Plot depicting the pattern of chromosomal involvement in LOH. Vertical columns represent chromosomal numbers and horizontal
rows represent patient numbers. LOH due to hemizygous deletions and cnLOH are represented by orange and gray, respectively. Twelve
chromosomes among 5 TSHomas showed LOH. cnLOH was more common than hemizygous deletions. Recurrent cnLOH was observed in
chromosomes 1 and 8. (B–F) SNP array data plotted on the chromosomal browser of KaryoStudio software to show LOH across tumors. The red
line depicts smoothened Log R, the log2 ratio of the observed to expected signal intensity signifying the copy number status (any deviation in Log
R from the normal value of 0 represents a copy number change). Blue dots represent the B-allele frequency (BAF). Heterozygous and
homozygous SNPs cluster around BAFs of 0.5 and 0 or 1, respectively. The numbers on top represent the chromosome involved in LOH. The gray
horizontal bars and orange bars represent the region found for cnLOH and LOH due to hemizygous deletions, respectively. Fig. 2(B–F) represents
LOH patterns in samples 1, 2, 4, 5, and 8, respectively.
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involving the genes CWH43, ASTN2, R3HDM2, and
SMOX occurred over chromosomes 4, 9, 12, and 20,
respectively.No samemutationwas confirmedwith Sanger
sequencing in more than 1 tumor, such that a recurrent
alteration was not identified in the discovery cohort.
Although an average of 1.5 putative somatic muta-
tions were identified per tumor, the number of mutations
varied across tumor samples. As shown in Table 3, tumor
sample 5 harbored 4 somatic DNA variants (SYTL3;
c.158A.G, ASTN2; c.1508C.T, R3HDM2; c.1276G.
A, SMOX; c.944T.C). Similarly, although tumor
samples 3 (CWH43; c.1240G.A) and 7 (ZSCAN23;
c.1069C.T) harbored 1 somatic DNA variant each,
tumor sample 6 harbored none. Tumor sample 5, with
the highest number of mutations, was the only sample
with cnLOH that was included in the WES study.
However, all DNA variants observed in this sample were
heterozygous, and no mutations were found in cnLOH
regions. This tumor sample was from the oldest patient,
who had the highest cell proliferation marker-labeling
index among the samples included for the WES study.
Identification of candidate driver mutations in the
validation cohort
The 6 SNVs confirmed in the discovery cohort were
subjected to a validation screen in a set of 8 tumors (tumor
samples 1, 2, 4, 8, and 9 to 12; Table 1) to identify re-
current mutations. Recurrent mutations were not found in
the validation set of 8 TSHomas, thereby indicating that
the detected mutations represent rare drivers for tumori-
genesis or passenger mutations and are unlikely to rep-
resent common driver mutations in TSHomas. No
mutations were found in known oncogenes, TSGs, or
genes previously implicated in other pituitary adenomas.
However, 2 genes mutated in tumor sample 5, namely
SMOX and SYTL3, have previously been implicated in
tumorigenesis and acted via oxidative DNA damage and
the Rab pathway, respectively (30–32).
Integration of SNP array and WES results
As shown in Supplemental Table 10, the integration of
our results from WES to the SNP array analysis revealed
copy number gains on chromosome 4p (position: 48283-
49553810) harboring the CWH43 gene in 50% of our
genotyped samples. Similarly, the copy number gains
on chromosome 9 (position: 71034203-141044489) in
37.5% of tumor samples harbored the ASTN2 gene loci.
Furthermore, copy number gains at chromosomes 12 and
20, each of which was observed in 25% of our genotyped
samples, harbored the loci for the R3HDM2 and SMOX
genes, respectively. Although concomitant gain in copy
number and mutation were observed together in the case
ofCWH43 in tumor sample 3, in all other tumor samples,
gain in copy numbers was not observedwith concomitant
mutation in genes. In addition, cnLOH at chromosome 6
(position: 27601587-32435044) on tumor sample 4
harbored loci for the ZSCAN23 gene, which was in-
volved in the mutation observed in tumor sample 7.
Table 2. Overview of Somatic DNA Variants Found in the Discovery Set of 4 TSHoma Samples
Tumor
Sample
No.
Variant
Type
Filter Steps
Qualitya →
On
Targetb →
Amino Acid Changec
→ Unknownd → Variants ConfirmedMissense Nonsense
Frame-
shift
Splice-
Site Insertions Deletions Total
3 SNV 132 41 14 1 0 0 0 0 15 3 1
Indel 111 0 0 1 2 3 4 10 0 0
5 SNV 130 36 13 2 0 0 0 0 15 6 4
Indel 120 0 0 2 0 4 1 7 0 0
6 SNV 141 36 16 0 0 0 0 0 16 2 0
Indel 102 0 0 5 2 0 2 9 0 0
7 SNV 158 53 24 0 0 1 0 0 25 5 1
Indel 109 0 0 3 2 3 3 11 1 0
Total 1003 67 3 11 7 10 10 108 17 6
Only the number of somatic variants at each filtering step is shown in the table, alongwith the variant types and functional classes. SomaticSniperwas used
to detect somatic SNVs, and somatic indels were called using the GATK SomaticIndel detector. Details of all 108 protein-altering variants with amino acid
change further indicating the unknown variants are presented in Supplemental Table 8.
aQuality refers to total number of high-quality somatic SNVs and tumor-specific indels.
bOn target refers to SNVs identified in the targeted region covered by the SureSelect Human All Exon V5 capture system used in this study (which captures
known coding DNA sequences from the National Center for Biotechnology Information Consensus CDS Database).
cAmino acid change refers to DNA variants with moderate to high predicted functional impacts on the encoded protein, as predicted by effect prediction
tool snpEFF.
dUnknown refers to variants not previously reported in the public databases, including dbSNP, 1000 Genome Project, and HapMap-JPT.
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Discussion
The current study characterized the comprehensive ge-
netic landscape of TSHomas using the combined ap-
proach of SNP array and WES. Our results suggest a
lower number of somatic SNVs in TSHomas (1.5 per
tumor) compared with that reported for surface-derived
malignant tumors (33). However, our results are in line
with previous findings among somatotropinomas (15)
and nonfunctioning pituitary adenomas (24), wherein
similar number of mutations per tumor were observed.
This finding highlights the lowmitotic activity and benign
nature of TSHomas.
The results of our WES study are consistent with
previous findings on pituitary adenomas with regard to
the absence of mutations in established classical onco-
genes and TSGs (15, 16, 24). However, in contrast to
previous studies of other pituitary adenomas, we found
no mutation involving the GNAS, GPR101, or USP8
genes (14–16, 18, 19). Nevertheless, the loci harboring
the genes USP8 and GNAS were involved in recurrent
amplification in our copy number analysis, thereby
highlighting the importance of investigating these genes
in future studies involving a larger cohort of TSHomas.
Although we did not find the same mutation in more
than 1 tumor, 6 SNVs were identified in the genes
CWH43, ZSCAN23, SYTL3, ASTN2, R3DHM2, and
SMOX. Two of these genes, SMOX and SYTL3, have
previously been implicated in the tumorigenesis of several
cancers. SMOX is involved in polyamine metabolism,
Figure 3. Sequences of mutations in TSHomas. Confirmatory Sanger traces from 4 tumor samples. Traces for blood and tumor genomic DNA are
shown for (A) ZSCAN23 gene codons 355 to 359 [note: c.1069 C.T; p.(Gly357Arg) at Chr6: g.28402343]. (B) SYTL3 gene codons 156 to 160
[note: c.158 A.G; p.(Asn53ser) at Chr6: g.159086474]. (C) ASTN2 gene codons 501 to 505 [note: c.1508C.T; p.(Trp503Stop) at Chr9:
g.119738995]. (D) R3HDM2 gene [note: c.1276G.A; p.(pro426ser) at Chr12: g.57674167]. (E) CWH43 gene codons 412 to 416 [note:
c.1240G.A; p.(Ala414Thr) at Chr4: g.49019319]. (F) SMOX gene [note: c.944 T.C; p.(Val315Ala) at Chr20:g.4163070].
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and Cag A of Helicobacter pylori has been shown to in-
duce its expression; this, in turn, leads to oxidative DNA
damage and rendering cells resistant to apoptosis, and,
hence, confers a high risk of gastric cancer (30). Similarly,
oxidative DNA damage resulting from an increase in the
expression of spermine oxidase has been described in
prostate cancer (31). SYTL3 has been shown to encode
synaptotagmin-like proteins, which play a role in vesicular
transport with their interaction with RAB27. The de-
regulation of this Rab pathway along with Rab effector
genes has been implicated in bladder cancer (32). Oxi-
dative DNA damage and the Rab effector pathway both
represent established pathways for tumorigenesis; how-
ever, further studies are needed to examine the functional
significance of these different pathways in TSHomas.
Using the SNP array technique for copy number esti-
mation, we identified aneuploidy as a common event in
TSHomas, as described previously for other pituitary
adenomas (15). The most recurrent chromosomal arm-
length gains were observed at 4p, 5p, 7p, 19q, 4q, 15q,
16p, 19p, and 21q. Although study findings have varied
regarding the patterns of chromosomal involvement in
gain or loss events in pituitary tumors (15, 20, 34), the
gains observed at chromosomal arms 4q, 5p, and 19q in
our study agreewith earlier findings reported by Pack et al.
(20). Notably, recurrent gains at 15q and 20q harbored
loci for the USP8 and GNAS genes, respectively. Besides
these chromosomal arm-length gains, copy number
analysis revealed several recurrent focal gains, of which
recurrent gain at the 1q31.1-32.1 loci is of special interest
because the BRINP3 gene at this locus was previously
implicated in gonadotrope-cell pituitary adenoma (26).
Furthermore, recurrent chromosomal amplifications
identified at regions harboring genes CWH43, ASTN2,
R3HDM2, and SMOX highlight the importance of our
results obtained fromWES. The significance of these genes
and loci of recurrent gains in relation toTSHomas have yet
to be elucidated; however, the genetic lesions identified
serve as a reference point for future studies aimed at
identifying candidate driver genes. One exceptional find-
ing during our SNP array analysis was the absence of any
detected copy number alteration in tumor sample 6; sur-
prisingly, in WES, no mutations were confirmed in the
same sample. These findings may reflect tumor sample 6
possibly representing the early stage of the disease; how-
ever, analysis of the duration of symptoms as well as the
age of patients with the observed number of copy-number
aberrations among all samples did not establish a pattern
or trend with regard to genetic evolution of the tumor.
Another important result of our SNP array analysis
was the chromothripsis-like pattern of copy number al-
terations observed for chromosomes 1 and 2 in tumor
sample 5. However, the accurate inference of breakpoint
rearrangements observed in chromothripsis is not pos-
sible from SNP array data alone (25). Furthermore, be-
cause chromothripsis has been reported in growth
hormone–secreting adenomas (15) and their potential for
tumorigenesis in benign tumors has been described for
uterine leiomyomas (35), our results in TSHomas need to
be confirmed further by using more reliable approaches,
such as massively parallel sequencing (25).
Our study provides evidence for cnLOH in TSHomas.
These genetic lesions have previously been described in
relation to various tumors (36–38). We did not examine
matched constitutive samples; however, we noted several
broader regions of cnLOH in contrast to the generally
lower size of germline-cnLOH reported in other study
(36). This suggests that some of these observed cnLOH
represent somatic uniparental disomy events. Further-
more, because these events were identified at regions of
segmental duplication and fragile sites, they may have
resulted from a recombination event or gene conversion
during the repair of double-strand breaks at these sites, as
described in various other tumors (36, 37, 39). However,
recurrent cnLOH events were observed only on chro-
mosome arms 1p and 8p. cnLOH at 1p encompasses loci
Table 3. Details of Somatic Variants Confirmed in the Discovery Set of 4 TSHomas
Position
Gene
Symbol Gene Name
Nucleotide
Change
Protein
Change Transcript
Mutation
Type
Predicted
Zygosity
Variant
Type
Tumor
Sample
No.
49019319 CWH43 Cell wall biogenesis
43 C-terminal
homolog
c. G1240A A414T NM_025087.2 Missense Heterozygous SNV 3
28402343 ZSCAN23 Zinc finger and
SCAN domain
containing 23
c. C1069T G357R NM_001012455.1 Missense Heterozygous SNV 7
159086474 SYTL3 Synaptotagmin-
like 3
c.A158G N53S NM_001009991.3 Missense Heterozygous SNV 5
119738995 ASTN2 Astrotactin 2 c.C1508T W503STOP NM_014010.4 Nonsense Heterozygous SNV 5
57674167 R3HDM2 R3H domain
containing 2
c.G1276A P426S NM_014925.3 Missense Heterozygous SNV 5
4163070 SMOX Spermine oxidase c.T944C V315A NM_175839.2 Missense Heterozygous SNV 5
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harboring the CDKN2C gene, the inactivation of which
by promoter methylation has been reported in up to 20%
of pituitary tumors (40). Although cnLOH may result in
the duplication of a methylated gene and cause the ef-
fective knockout of TSG, causing clonal selection, further
epigenetic approaches need to be used to verify the in-
volvement of such a mechanism (36).
The current study examined somatic events in
TSHomas; however, some caveats are worth noting. The
sample size used for the study was small. To investigate
this rare tumor, we used a set of 12 samples, 4 of which
were used in the discovery cohort for WES. Multicenter
studies with more TSHomas may enhance the landscape
of somatic genetic events further. Furthermore, in our
SNP array analysis, we relied on manufacturer-provided
cluster files to obtain genotype calls. Studies involving a
higher-resolution SNP array from constitutive matched
pair samples along with the inclusion of mixing studies
may lead to the more accurate identification of somatic
cnLOH events.
In conclusion, we identified several candidate somatic
mutations and changes in copy numbers in TSHomas.
Our results showed no recurrence of mutations in the
tumors studied but a low number ofmutations per tumor,
thereby highlighting their benign nature. Further studies
on a larger cohort of TSHomas, in combination with
epigenetic and transcriptomic approaches, may reveal the
underlying genetic lesions.
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